\
&
Contact us
\
&
Contact us
This was 1 year ago
LocationAmsterdam, Netherlands
The EuroHPC Joint Undertaking and the EuroCC Netherlands organise the second EuroHPC User Day to bring together the EuroHPC Users community.
Attendees will be able to showcase EuroHPC projects that have used European HPC supercomputing resources, share best practices in the development of these projects, gather feedback from EuroHPC users and engage with potential new users.
Users of the EuroHPC JU systems are invited to present their work and the opportunity to submit papers setting the results of the projects that used EuropHPC resources. Papers need to show scientific excellence in the chosen thematic fields. The manuscripts can be submitted here before August 15, 2024. The papers should be a max of 10 pages and should contain an explanation of the experiment undertaken and what compute power of the supercomputer was used for.
For more information on the event, the conditions to submit papers and to register for the event please visit the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
